Edesa Biotech, Inc. shareholders approved Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year at the 2026-09-30 meeting.
“Proposal No. 4 - Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year The shareholders approved the appointment of MNP LLP as the Company’s auditors and independent registered public accounting firm for the fiscal year ending September 30, 2026. For Withhold Broker Non-Votes 4,814,478 87,443 N/A”
Shareholder Votes
Edesa Biotech, Inc. shareholders approved Approval of Amendment to the 2019 Equity Incentive Compensation Plan.
“Proposal No. 3 - Approval of Amendment to the 2019 Equity Incentive Compensation Plan The shareholders approved an amendment to the Company’s 2019 Plan to (i) increase the number of shares available for issuance thereunder plan by 750,000 shares and (ii) eliminate the annual per participant option grant limit. For Against Abstain Broker Non-Votes 2,613,551 130,589 10,680 2,147,101”
Shareholder Votes
Edesa Biotech, Inc. shareholders approved Advisory Vote on Executive Compensation.
“Proposal No. 2 - Advisory Vote on Executive Compensation The shareholders approved, on an advisory basis, the executive compensation of the named executive officers as disclosed in the proxy statement for the Annual Meeting, by the following vote. For Against Abstain Broker Non-Votes 2,670,075 69,281 15,464 2,147,101”
Shareholder Votes
Edesa Biotech, Inc. shareholders approved Election of the Company’s Directors.
“Proposal No. 1 - Election of the Company’s Directors Based upon the following votes, the shareholders elected Joan Chypyha, David Liu, Sean MacDonald, Patrick Marshall, Pardeep Nijhawan, Charles Olson and Carlo Sistilli to serve as members of the Company’s board of directors until the annual meeting of shareholders to be held in 2027 or until their successors are duly elected and qualified. For Withhold Broker Non-Votes Joan Chypyha 2,705,856 48,964 2,147,101 David Liu 2,674,286 80,534 2,147,101 Sean MacDonald 2,674,082 80,738 2,147,101 Patrick Marshall 2,706,023 48,797 2,147,101 Pardeep Nijhawan 2,705,297 49,523 2,147,101 Charles Olson 2,705,959 48,861 2,147,101 Carlo Sistilli 2,673,724 81,096 2,147,101”
Peter J. Weiler was appointed as Chief Financial Officer at Edesa Biotech, Inc..
“the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025”
Stephen Lemieux resigned as Chief Financial Officer at Edesa Biotech, Inc..
“Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.”
David Liu was appointed as Director at Edesa Biotech, Inc..
“the Company appointed David Liu, the Lead Investor Nominee, to serve on the Board of Directors”
Earnings Releases
Edesa Biotech, Inc. reported the six months ended March 31, 2024 results: net income $3.5 million for the six months ended March 31, 2024, EPS $1.12 per common share.
“For the six months ended March 31, 2024, Edesa reported a net loss of $3.5 million, or $1.12 per common share”
Earnings Releases
Edesa Biotech, Inc. reported the three and six months ended March 31, 2024 results: net income $1.9 million for the quarter ended March 31, 2024, EPS $0.58 per common share.
“For the quarter ended March 31, 2024, Edesa reported a net loss of $1.9 million, or $0.58 per common share”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.